文献速递免疫规划传染病防控与疫情报告

IgG-Fc融合COVID-19亚单位疫苗AKS-452的I/II期研究I期中期结果

Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
PubMed 文献 · Vaccine · 2022-01-31

这项单中心、开放标签、I期剂量探索研究纳入60名18-65岁健康成人,按22.5、45、90 µg分六个队列(每队列10人),间隔28天接种一或两剂AKS-452。主要终点为安全性和反应原性,次要终点为免疫原性。未发生≥3级不良事件、归因于AKS-452的严重不良事件或SARS-CoV-2感染;第28天抗SARS-CoV-2 SP/RBD IgG血清阳转率在22.5、45、90 µg队列分别为70%、90%、100%,第56天均升至100%(单剂22.5 µg队列为89%)。

要点

  • 研究未发生≥3级不良事件、归因于AKS-452的严重不良事件或SARS-CoV-2感染。
  • 第28天血清阳转率22.5 µg队列70%、45 µg队列90%、90 µg队列100%。
  • 第56天血清阳转率均达100%,单剂22.5 µg队列为89%。

核心结论

  • AKS-452的I期研究显示良好的安全性和免疫原性特征,支持启动II期研究。
  • 该疫苗可在室温下稳定保存,可快速低成本生产,无需复杂分销或冷链即可在全球范围接种。

研究设计与样本

  • 单中心、开放标签、I期剂量探索和安全性研究。
  • 纳入60名18-65岁健康成人,接受间隔28天的一剂或两剂22.5 µg、45 µg或90 µg AKS-452,共六个队列,每队列10人。
  • 主要终点为安全性和反应原性,次要终点为免疫原性评估。
  • 疫苗为SARS-CoV-2病毒刺突蛋白受体结合域(SP/RBD)抗原与人IgG1 Fc的融合蛋白,以油包水佐剂Montanide™ ISA 720乳化。
  • 临床试验注册号:NCT04681092。

主要发现

  • 研究期间未发生≥3级不良事件、归因于AKS-452的严重不良事件或SARS-CoV-2病毒感染。
  • 第28天抗SARS-CoV-2 SP/RBD IgG血清阳转率:22.5 µg队列70%、45 µg队列90%、90 µg队列100%。
  • 第56天血清阳转率均升至100%,单剂22.5 µg队列为89%。
  • 所有IgG滴度呈Th1同种型偏倚,可有效结合多种SARS-CoV-2变异株的突变SP/RBD。
  • 对活病毒感染细胞显示强中和效力,包括alpha和delta变异株。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To address the coronavirus disease 2019 (COVID-19) pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recombinant subunit vaccine, AKS-452, is being developed comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain (SP/RBD) antigen and human IgG1 Fc emulsified in the water-in-oil adjuvant, Montanide™ ISA 720. A single-center, open-label, phase I dose-finding and safety study was conducted with 60 healthy adults (18-65 years) receiving one or two doses 28 days apart of 22.5 µg, 45 µg, or 90 µg of AKS-452 (i.e., six cohorts, N = 10 subjects per cohort). Primary endpoints were safety and reactogenicity and secondary endpoints were immunogenicity assessments. No AEs ≥ 3, no SAEs attributable to AKS-452, and no SARS-CoV-2 viral infections occurred during the study. Seroconversion rates of anti-SARS-CoV-2 SP/RBD IgG titers in the 22.5, 45, and 90 µg cohorts at day 28 were 70%, 90%, and 100%, respectively, which all increased to 100% at day 56 (except 89% for the single-dose 22.5 µg cohort). All IgG titers were Th1-isotype skewed and efficiently bound mutant SP/RBD from several SARS-CoV-2 variants with strong neutralization potencies of live virus infection of cells (including alpha and delta variants). The favorable safety and immunogenicity profiles of this phase I study (ClinicalTrials.gov: NCT04681092) support phase II initiation of this room-temperature stable vaccine that can be rapidly and inexpensively manufactured to serve vaccination at a global scale without the need of a complex distribution or cold chain.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Janssen YF, Feitsma EA, Boersma HH, et al. Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine. 2022. PMID: 35115195. doi:10.1016/j.vaccine.2022.01.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。